Abstract: Checkpoint kinase 2 (Chk2), a ser/thr kinase involved in the ATM-Chk2 checkpoint pathway, is activated by genomic instability and DNA damage and results in either arrest of the cell cycle to allow DNA repair to occur or apoptosis if the DNA damage is severe. Drugs that specifically target Chk2 could be beneficial when administered in combination with current DNAdamaging agents used in cancer therapy. Recently, a novel inhibitor of Chk2, NSC 109555, was identified that exhibited high potency (IC 50 = 240 nM) and selectivity. This compound represents a new chemotype and lead for the development of novel Chk2 inhibitors that could be used as therapeutic agents for the treatment of cancer. To facilitate the discovery of new analogs of NSC 109555 with even greater potency and selectivity, we have solved the crystal structure of this inhibitor in complex with the catalytic domain of Chk2. The structure confirms that the compound is an ATP-competitive inhibitor, as the electron density clearly reveals that it occupies the ATPbinding pocket. However, the mode of inhibition differs from that of the previously studied structure of Chk2 in complex with debromohymenialdisine, a compound that inhibits both Chk1 and Chk2. A unique hydrophobic pocket in Chk2, located very close to the bound inhibitor, presents an opportunity for the rational design of compounds with higher binding affinity and greater selectivity.
Introduction
Checkpoint kinase 2 (Chk2) is a tumor suppressor protein that participates in the regulation of the cell cycle in response to DNA damage by phosphorylating a number of downstream targets involved in cell cycle arrest, DNA damage repair, and apoptosis. [1] [2] [3] Chk2 is debromohymenialdisine (DBQ) revealed a novel dimeric arrangement of kinase molecules in which the activation loops are exchanged between adjacent kinase domains to facilitate the trans-autophosphorylation mechanism. 6, 8 On activation, Chk2 phosphorylates a number of downstream targets involved in cell cycle arrest such as Cdc25A, Cdc25C, BRCA1, and/or proteins that play a functional role in apoptosis such as p53, PML, and E2F1 [for review see Refs. 9 and 10]. There are two main rationales for the development of Chk2 inhibitors. 11 First, studies have shown that Chk2 is activated in precancerous lesions with genomic instability 12, 13 and cancer cells grown in culture. 14, 15 Moreover, Chk2 has been shown to play an important role in the release of survivin, a protein implicated in tumor survival, from the mitochondria following DNA damage, 16 and in tumor cell adaptation to changes that result from the cycling nature of hypoxia and reoxygenation found in solid tumors. 17 Thus, a selective inhibitor of Chk2 is of considerable interest as it may result in the death of cells with endogenous activation of Chk2 in response to Chk2 inhibition. Second, selective inhibition of Chk2 in p53-deficient tumor cells may increase their sensitivity to chemotherapeutics and radiation by targeting the G2 checkpoint. 9, [18] [19] [20] Previously, it has been shown that down-regulation of Chk2 in p53-defective tumor cells results in enhanced apoptotic activity in response to ionizing radiation. 21 Thus, targeted inhibition of Chk2 could potentially result in an increase in the therapeutic effects of DNA-targeting agents in p53-defective tumors. 9, 20, 22 Additionally, because of the role of p53
in the initiation of apoptosis in response to DNA damage, inhibition of Chk2 in normal cells may also protect normal tissues, 1, 23 which may reduce side effects due to chemotherapy or radiation therapy. 24 Because only a few specific inhibitors of Chk2 have been identified to date, [24] [25] [26] [27] [28] [29] [30] the discovery of additional inhibitors remains of considerable interest. A novel inhibitor of Chk2, NSC 109555 [ Fig. 1(A) ], was recently identified by our laboratories using a highthroughput screening assay. 29 NSC 109555 is an ATPcompetitive inhibitor that represents a new chemotype for a Chk2 inhibitor with high potency (IC 50 ¼ 240 nM) and selectivity. Seeking to understand the mode of inhibition of Chk2 by NSC 109555, we cocrystallized the catalytic domain of Chk2 with the inhibitor and refined the structure to a resolution of 2.05 Å. These results provide detailed structural insight into the protein-inhibitor interactions and establish an opportunity for structure-assisted optimization of NSC 109555 and the development of new inhibitors of Chk2.
Results and Discussion
Crystallization and overall structure
Initial cocrystallization trials searching for diffraction quality crystals of the Chk2 catalytic domain in complex with NSC 109555 failed to yield single crystals or did not result in any crystals at all. Thus, streak seeding was used to obtain single crystals of the Chk2-NSC 109555 complex using previously grown Chk2-ADP crystals as a seed source. The crystals diffracted X-rays to 2.05 Å resolution and the structure was solved by molecular replacement using the coordinates of the Chk2-ADP complex as a search model (PDB code: 2CN5). The resulting 2F o À F c and F o À F c electron density maps enabled unambiguous placement of NSC 109555 into the ATP-binding pocket of Chk2 [ Fig.  1(B) ]. The refined structure exhibited a working R-factor of 0.22 and R-free of 0.25. The Ramachandran plot obtained from an analysis of the coordinates resulted in more than 90% of the residues in the most-favored region and no residues in the disallowed region. X-ray data collection and refinement statistics are summarized in Table I .
Binding mode of NSC 109555
The biochemical characterization of NSC 109555 indicated that it is a potent competitive inhibitor of ATP binding, exhibiting an IC 50 of 240 nM. 29 The cocrystal structure of Chk2 with NSC 109555 confirms that the inhibitor interacts with the ATP-binding pocket in an elongated manner (see Fig. 2 ) but more importantly, the mode of binding differs from what had been previously predicted by molecular modeling. 29 In the binding mode predicted by computational methods, the inhibitor adopted a ''horse-shoe'' conformation with hydrogen bonds to Leu226, Asp311, Asp328, and Glu351. The electron density maps, however, clearly reveal that NSC 109555 is anchored to the ATP-binding pocket in an extended conformation via hydrogen bonding of the guanidinium terminus to Glu273, which is located on the C-a helix (see Fig. 3 ). Additional interactions with the ATP-binding pocket occur via water-mediated hydrogen bonds between the carbonyl group of the urea functional group of the inhibitor with the backbone carbonyl of Glu302 and the amide of Met304. The aryl moieties of the phenyl guanidinohydrazone also contribute to binding affinity via van der Waals interactions with Val 234, Lys249, Ile299, Leu301, and Leu354 resulting in highly favorable surface complementarity between the inhibitor and the ATP-binding pocket. The cocrystal structure reveals the presence of a hydrophobic pocket in Chk2 which is directly accessible by the methyl group adjacent to the guanidylhydrazone moiety that is bound to Glu273 [ Fig. 4(A) ]. The size and location of this cavity is such that it could accommodate additional substituents on the methyl group.
Insights into structure-activity relationships for NSC 109555
Prior structure-activity relationship (SAR) studies of NSC 109555 using structural analogs (see Table II in Ref. 29) suggested that the guanidylhydrazone and urea groups are important for the activity of NSC 109555. With the availability of the cocrystal structure, it is now possible to correlate these studies with important aspects of the protein-inhibitor interactions. For example, compounds NSC 177944 (meta-substituted analog) and NSC 177941 (meta-substituted analog with a urea to thiourea substitution) were both inactive against Chk2. The meta-substituted analog would result in different orientations of the urea and Crystal Structure of a Chk2/Inhibitor Complex guanidylhydrazone, thereby disrupting the water-mediated hydrogen bonds between the urea carbonyl and the backbone of Glu302 and Met304, and would also disrupt the binding of the guanidinium terminus to Glu273, which appears to be a critical residue for anchoring the inhibitor in the active site. Furthermore, the van der Waals interactions between the protein and both aryl groups in NSC 109555 appear to be structurally important, as replacement of these groups by a different linker, such as in NSC 67931 (a single phenyl group) or NSC 69432 (an aliphatic group), renders the molecules inactive against Chk2. The urea functional group also appears to be an important structural feature because replacing it with a thiourea group, as in the case of NSC 177940, results in an inactive compound. This can be rationalized in terms of the less electronegative character of the C¼ ¼S bond which could potentially disrupt the water-mediated hydrogen bonds to Glu302 and Met304. Although this molecule is missing one of the terminal guanidylhydrazone groups, the second guanidylhydrazone group does not appear to make any strong contacts with the ATP-binding pocket in the crystal structure.
Comparison with the Chk2-DBQ and Chk2-ADP structures
To gain additional insight into the high specificity of NSC 109555 for Chk2, we compared the cocrystal structure with the previously determined structure of Chk2 in complex with DBQ at 2.70 Å resolution. 6 DBQ is an ATP-competitive inhibitor with an IC 50 below 183 nM for Chk2 but it is not specific for Chk2. 10, 25, 29 Overall, the global structures of the protein molecules in the two cocrystal structures are almost identical. The binding mode of DBQ (see Fig. 5 ) differs from that of NSC 109555 in that it exhibits direct hydrogen bonding interactions with the backbone of the hinge residues Glu302 and Met304 and an additional extensive hydrogen bonding network involving residues Glu308 and Asn352. In contrast, there are no direct hydrogen bonds between NSC 109555 and the hinge region. Rather, there are water-mediated hydrogen bonds between the urea carbonyl and the backbone of the hinge residues Glu302 and Met304. Furthermore, there are no polar or water-mediated interactions between DBQ and the ATP-binding pocket, unlike NSC 109555, which exhibits both water-mediated hydrogen bonds and a polar interaction between the guanidinium terminus and Glu273. Another significant difference between the structures is the orientation of Lys249. In the structures of Chk2 in complex with ADP and DBQ, the Lys249 residue is positioned closer to Glu273. However, on binding of NSC 109555 the side chain of Lys249 shifts approximately 3.9 Å away from Glu273 such that the aliphatic portion of the former residue packs against the aryl ring of NSC 109555, thereby eliminating its interaction with the latter residue. These two residues are strictly conserved among kinases and the lysine plays an important structural role by coordinating the a-and b-phosphates of ATP. A common feature among kinases is a salt-bridge between these two residues that couples the conformation of the C-a helix with nucleotide binding. 31 Another difference between the structures is that the glycine-rich phosphate binding loop (P-loop) is disordered in the Chk2-NSC 109555 complex (residues 229-231 lack electron density) whereas the same loop is well defined in the Chk2-ADP complex. Interestingly, the P-loop is also disordered in the Chk2-DBQ complex. This suggests that this loop undergoes some dynamic changes in Chk2 on inhibitor binding.
Structural insights into Chk2 selectivity
The IC 50 of NSC 109555 for Chk2 is 240 nM whereas its IC 50 for Chk1 is greater than 10 lM. 29 NSC 109555 also exhibits high selectivity for Chk2 against a panel of 20 kinases. 29 The availability of the cocrystal structure of Chk2 in complex with NSC 109555 enabled us to identify structural features that may contribute to the high selectivity of NSC 109555 for Chk2 over Chk1 and other kinases. In general, the ATP-binding pockets of Chk2 and Chk1 are highly conserved, but there are some notable differences. The most significant of these are in the hinge loop where Chk2 residues Leu303, Met304, and Glu305 are replaced by Tyr, Cys, and Ser in Chk1, respectively. Additionally, residue Thr367 of Chk2 (located proximal to the aryl ring of NSC 109555) is a serine in Chk1. Portions of the glycinerich P-loop in Chk2, which is located directly above the inhibitor, are disordered (residues 229-231), whereas this loop is well-defined in the structure of Chk1. There are also sequence differences between Chk2 and Chk1 in this glycine-rich loop (P-loop). The P-loop contains a sequence motif that is highly conserved among kinases, GXGXUG, where U is usually a Tyr or Phe residue. 31 In Chk2, the U position is occupied by Cys231 whereas in Chk1 this residue is a bulkier tyrosine. The P-loop is known to be conformationally flexible, which allows it to accommodate inhibitors that induce large structural distortions in this loop by interacting with the conserved aromatic U residue. 31 Indeed, a structural alignment of Chk2 and Chk1 [apo form (PDB code:1IA8) and in complex with an inhibitor (PDB code: 2C3K)] reveals differing conformations of this loop which results in different shapes of the ATP-binding pockets in the two proteins. The structural features of the Chk1 ATP-binding pocket also reveal that steric hindrance of Glu55 (Glu 273 in Chk2) by the neighboring Tyr20 and Lys38 residues may prevent the guanidinium terminus of NSC 109555 from forming hydrogen bonds with Glu55, which would likely reduce the binding affinity [ Fig. 4(B) ]. Seeking further insight into the high selectivity that the inhibitor exhibits for Chk2, we also examined crystal structures of other kinases that were screened for inhibition by NSC 109555. 29 The conformation of NSC 109555 that is observed in the cocrystal structure with Chk2 did not fit into the ATP-binding pockets of any of these kinases without encountering some type of steric impediment. For example, the guanidinium terminus was sterically hindered from optimally interacting with the homologous glutamate residues (Glu273 in Chk2) in all of the structures examined, although in some instances small changes in the positioning of side chains near the glutamate would make it more accessible. Also, the orientation of the C-a helix on which Glu273 is located differs slightly in some structures when compared with Chk2, thereby altering the orientation of the glutamate side chain. In certain examples such as C-Met (PDB code: 1RLW), AKT (PDB code: 2GU8), and p38 (PDB code: 1KV1) kinases, against which NSC 109555 was found to be poorly active (IC50 > 10 lM), the inhibitor had a very poor fit to the ATP-binding pocket due to multiple steric constraints. [32] [33] [34] This analysis is, of course, qualitative in nature as there are more influences on inhibitor binding than just steric interactions. For instance, overall protein dynamics may influence the selectivity of kinases for inhibitor binding, as has been observed in some instances. 31 The conformation of the P-loop also differs significantly in these enzymes, which may influence access of the inhibitor to the ATP-binding pocket. Interestingly, all of these kinases have either a Phe or Tyr residue in the U position of the GXGXUG motif in the P loop, in contrast to Chk2, which has a smaller cysteine residue with different chemical properties. Structural alignment of Chk2 with the ser/thr kinase PIM-1 (PDB code: 2OBJ) illustrates the highly conserved nature of their ATP-binding pockets, with the notable exception of Pro123 in the hinge region of PIM-1, which corresponds to Met304 in Chk2. This Pro residue is unable to maintain a hydrogen bond network to the urea group of NSC 109555 because it lacks the amide hydrogen, but the inhibitor could potentially maintain the guanidinium-glutamate interaction. 35 Nevertheless, NSC 109555 was found to be poorly active against PIM-1 kinase (IC 50 >10 lM).
Implications for drug design
The determination of the cocrystal structure of the catalytic domain of Chk2 in complex with NSC 109555 presents a new opportunity for the structure-assisted design of novel Chk2 inhibitors based on a highly potent and selective lead compound. The combination of high-throughput screening and structural biology has proven to be a powerful tool for guiding the optimization of the pharmacological properties of lead compounds in the design of specific protein kinase inhibitors. [36] [37] [38] Among the important features discovered from the cocrystal structure reported herein are the water-mediated hydrogen bonds between the urea group of NSC 109555 and the hinge region of Chk2, the van der Waals interactions between the aryl moiety
Crystal Structure of a Chk2/Inhibitor Complex of the phenyl guanidinohydrazone and the ATP-binding pocket, the polar interactions between the guanidinium terminus and Glu273, and the hydrophobic pocket adjacent to Glu273. It will be of particular interest to ascertain whether the binding affinity of the inhibitor can be increased by optimizing its interactions with the hydrophobic pocket. This can be explored by examining the effects of new substituents on the methyl group of NSC 109555, such as branched and cyclic alkanes that may fill this pocket and interact via hydrophobic packing. This may present an opportunity to modulate the specificity of inhibitors as well, because the shape and degree of hydrophobicity of this pocket varies quite a bit among kinases. 36, 37 For instance, in Chk2 the pocket is surrounded entirely by hydrophobic residues. Although the corresponding pocket in Chk1 is also primarily hydrophobic, one polar residue, Asn59 (Leu 277 in Chk2), is also present. 39 In other kinases, access to this pocket is entirely blocked. For example, when the structure of Chk2 is compared with those of Zap (PDB code: 1U59) and EGFR (PDB code: 1XKK), it is self evident that full access to this pocket is impeded by two bulkier methionine residues in the latter two enzymes whereas the analogous residues are Leu277 and Leu301 in Chk2. 40, 41 Leu301 in Chk2 corresponds to the ''gatekeeper'' residue in many kinases, 42 which has been found to form contacts with bound inhibitors and is poorly conserved. Accordingly, differences in this position appear to account for the selectivity of many kinase inhibitors by modulating access to the hydrophobic pocket. 43 Indeed, inhibitors that were designed to interact with the homologous pocket in Chk1 showed increased binding affinity and selectivity for Chk1. 39 Thus, this pocket is of considerable interest for the design of new inhibitors with greater potency and specificity for Chk2. Another issue that may now be addressed is the exploration of alternate functional replacements for the guanidine moiety of NSC 109555. The highly basic nature of the guanidine group (pKa $ 12) may reduce cellular permeability and so a functional replacement that maintains the hydrogen bonding with Glu273 but has a lower pKa would be highly desirable.
Conclusions
The crystal structure of the catalytic domain of Chk2 in complex with a highly potent and selective inhibitor, NSC 109555, has been solved and provides a new template and chemotype for structure-assisted design of novel Chk2 inhibitors. The structure reveals binding interactions between NSC 109555 and the ATP-binding pocket that differ significantly from those observed in the previously reported structure of Chk2 in complex with DBQ, an inhibitor that does not exhibit selectivity for Chk2. A hydrophobic pocket near Glu273 of the ATP-binding pocket could potentially be exploited to improve the selectivity and binding affinity of the inhibitor by incorporating new functional groups aimed at optimizing the interactions between the inhibitor and the pocket. The design of specific inhibitors of protein kinases continues to remain a significant challenge. However, these crystallographic results provide new information that will facilitate the rational design of novel Chk2 inhibitors that may not only be useful therapeutic agents for the treatment of cancer, but also as molecular tools for biological studies of Chk2. To this end, we are continuing to develop and test additional analogs of NSC 109555.
Methods

Cloning, protein expression, and purification
The catalytic domain of human Chk2 (Ser210-Glu531) was amplified from the full-length cDNA clone by the polymerase chain reaction (PCR) using the following oligonucleotide primers: protease. 45 The digest was applied to a 30 mL Ni-NTA superflow column equilibrated in buffer A and the catalytic domain emerged in the column effluent. The column effluent was incubated overnight with 10 mM dithiothreitol, concentrated using an Amicon YM10 membrane, and applied to a HiPrep 26/60 Sephacryl S-100 HR column equilibrated with 25 mM Tris (pH 7.2), 150 mM NaCl, 2 mM tris(2-carboxyethyl)phosphine buffer. The peak fractions containing recombinant catalytic domain were pooled and concentrated to 35-45 mg/mL (estimated at 280 nm using a molar extinction coefficient of 32,890 M À1 cm À1 ). Aliquots were flash-frozen in liquid nitrogen and stored at À80 C. The final product was judged to be >90% pure by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The molecular weight was confirmed by electrospray ionization mass spectrometry.
Crystallization and data collection
All crystallization reagents were obtained from Hampton Research (Aliso Viejo, CA). NSC 109555 was supplied by the Drug Synthesis and Chemistry Branch, Developmental Therapeutics Program, National Cancer Institute, Rockville, MD, dissolved in neat DMSO and stored at À80 C. To obtain diffraction quality crystals of Chk2 in complex with NSC 109555, streak seeding was necessary. First, crystals of Chk2 in complex with ADP were grown as previously described and were used as seed sources. 6 A solution of 10 mg/mL Chk2 in 25 mM Tris pH 7.2, 150 mM NaCl, 2 mM TCEPwas incubated with 1 mM NSC 109555 (dissolved in neat DMSO) such that the final DMSO concentration in the protein-inhibitor mixture was 10% v/v. The mixture was incubated at room temperature for 30 min followed by an additional incubation for 1.5 h at 4 C. Insoluble compound was removed by centrifugation before crystallization setup. Crystals were grown using the hanging-drop vapor diffusion technique. A 1:1 ratio of protein-inhibitor solution and well solution (0.1M HEPES pH 7.8, 0.1M magnesium nitrate, 14% w/v polyethylene glycol 3350, and 16% v/v ethylene glycol) were mixed and the drops were sealed over 1 mL of well solution. The tray was incubated at 4 C overnight and the drops were streak-seeded the following day by transferring microseeds from the Chk2-ADP crystal to the drops with a whisker. Crystals grew to final dimensions of 0.3 mm Â 0.1 mm Â 0.1 mm within 3-7 days. The crystals were removed from the drop with a litho-loop and were immediately flash frozen in liquid nitrogen. X-ray diffraction data were collected from a single crystal held at approximately 100 K at beamline 22-ID (SER-CAT) of the Advanced Photon Source. A data set at 1.0 Å wavelength consisting of 120 images was collected using a 1.0 oscillation angle and a 3 s exposure time. The data were integrated and scaled using HKL3000. 46 The crystals for the Chk2-NSC 109555 complex belong to space group P3 2 21 with unit cell dimensions a ¼ b ¼ 90.9, c ¼ 93.6 Å and contain 1 molecule in the asymmetric unit (Matthew's coefficient 3.1, 59.7% solvent content). 47 The Chk2-NSC 109555 complex structure was solved by molecular replacement using the MOLREP program from the CCP4 suite. 48 The coordinates of the Chk2-ADP structure (pdb code: 2CN5) were used as a search model after removing all solvent and ligand molecules. 6 Cross-rotation and translational searches for 1 molecule in the asymmetric unit were conducted using a resolution range of 15-2.5 Å followed by rigid body refinement with REFMAC5. The model was rebuilt and corrected using cross-validated ra-weighted 2F o À F c and F o À F c maps 49 with COOT 50 and refined with REFMAC5. The progress of the refinement was monitored by setting aside 5% of the reflections for use in calculation of the R-free value. 51 The coordinates for the NSC 109555 molecule and appropriate chemical restraints and topology files were prepared using the Dundee PRODRG 52 server and the location of the inhibitor was determined using the F o À F c maps contoured at 3r level. Water molecules were added with COOT after the working R-factor dropped below 0.3 and were refined with REFMAC5. The model was refined to a working R-factor of 0.22 and an R-free of 0.25. Model validation was performed using MolProbity. 53 The coordinates and structure factors for the Chk2 catalytic domain in complex with NSC 109555 were deposited in the Protein Data Bank with accession code 2W0J. All molecular superpositions and figures were made using Pymol (Delano Scientific LLC, Castro City, CA).
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